Patent US4468382A successfully refreshed from Google Patents.
US4468382A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polypeptide-toxin hybrid protein
Assignee: Tufts Medical Center Inc
•
Filing: 1982-07-15
•
Granted: 1984-08-28
•
Expires: 2002-07-15
Abstract
Abstract A hybrid protein toxic to cells having linear neuropeptide receptors such as TRH receptors comprising a linear neuropeptide such as TRH covalently bonded to CRM 45 is useful for treatment of tumors.
Inventors
- 👤 Patricia Bacha
- 👤 Seymour Reichlin
- 👤 John R. Murphy
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 23:30
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/195; C07K14/34; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6811; A61K47/6817; C07K19/00; A61K38/00
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
14 words
A hybrid protein comprising TRH covalently bonded through a disulfide linkage to CRM 45.
Claim 2
Dependent Claim
14 words
A hybrid protein comprising TRH covalently bonded through a disulfide linkage to CRM 45.
Claim 3
Dependent Claim
29 words
A hybrid protein as claimed in claim 1 in which said bonding is between the histidyl imidazole group of said TRH and an amino group of said CRM 45.
Claim 4
Dependent Claim
29 words
The method of inhibiting protein synthesis in cells carrying TRH linear neuropeptide receptors which comprises bringing into contact with said cells a hybrid protein as claimed in claim 1.
Claim 5
Dependent Claim
31 words
A therapeutic composition toxic only to cells carrying receptors for TRH linear neuropeptide which comprises a hybrid protein as claimed in claim 1 together with a physiologically acceptable non-toxic carrier thereof.
Claim 6
Dependent Claim
30 words
The method as claimed in claim 3 in which said hybrid protein is bonded between the histidyl imidazole group of said TRH and an amino group of said CRM 45.
Claim 7
Dependent Claim
30 words
A therapeutic composition as claimed in claim 4 in which said hybrid protein is bonded between the histidyl imidazole group of said TRH and an amino group of said CRM45.
References Cited (Backward Citations)
US4340535A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-08-28 | 1988-02-27 | 1988-08-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-08-28 | 1992-02-27 | 1992-08-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-08-28 | 1996-02-27 | 1996-08-28 | $7700.00 | Window Closed / Lapsed |